Lupus and Pregnancy
Table of Contents
- Why This Matters
- Preconception — The Six-Month Rule
- Risk Stratification: Who Counts as High-Risk
- Antiphospholipid Syndrome and Anticoagulation
- Anti-Ro/SSA, Congenital Heart Block, and Neonatal Lupus
- Medications Usually Continued
- Medications Stopped Before Conception
- Biologics — Belimumab, Rituximab, and Anifrolumab
- Preeclampsia vs. Lupus Flare
- Prenatal Monitoring Schedule
- Delivery and Postpartum
- Breastfeeding
- Key Research Papers
- Connections
- Featured Videos
Why This Matters
If you have lupus and you want children, the good news up front: most pregnancies in women with lupus end with a healthy baby and a healthy mom. Twenty years ago rheumatologists routinely told lupus patients not to get pregnant. That advice is outdated. With modern risk-stratification and the right medication plan, live-birth rates exceed 80% — and in low-risk patients they approach the general-population rate.
But lupus pregnancy is not ordinary pregnancy. It sits at a complicated intersection: an autoimmune disease that can flare, a placenta that can fail, a panel of autoantibodies that can cross into fetal circulation, a list of medications that must be reshuffled, and a pregnancy complication (preeclampsia) that looks almost identical to one of the things lupus does on its own. The risks are real and include preeclampsia, preterm birth, intrauterine growth restriction, pregnancy loss, congenital heart block, and neonatal lupus. Nearly every one of those risks can be dramatically reduced by planning pregnancy carefully, staying on the right drugs, and getting watched closely by a team that knows what they are doing.
This article is the patient-facing version of what a maternal-fetal medicine specialist and rheumatologist would sit down and explain to you over an hour in a co-management clinic. Nothing here replaces that conversation — but it will help you show up prepared, ask the right questions, and catch errors when they happen.
Preconception — The Six-Month Rule
Rheumatologists commonly use a simple rule: how stable lupus was in the six months before conception shapes how the pregnancy goes. The 2020 American College of Rheumatology (ACR) guideline encourages conception during periods of quiet disease, on medications that are compatible with pregnancy. The largest study of which women do well is the PROMISSE study (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus), a prospective multicenter cohort of 385 lupus pregnancies. It did not test the six-month rule itself: it enrolled only women with quiet or stable lupus and looked for what predicted trouble among them. Women with high disease activity were excluded.
What PROMISSE showed:
- Overall, 19.0% of pregnancies had an adverse outcome: fetal death in 4%, newborn death in 1%, delivery before 36 weeks in 9% and a very small baby in 10%. Severe flares were uncommon: 2.5% in the second trimester and 3.0% in the third.
- Women with none of the baseline risk factors below had an adverse-outcome rate of 7.8%.
- Women who had lupus anticoagulant, or who did not have it but were nonwhite or Hispanic and using blood pressure medicine, had an adverse-outcome rate of 58.0%, and fetal or newborn death in 22.0%.
- The baseline predictors of a bad outcome were lupus anticoagulant (odds ratio 8.32), blood pressure medicine use (odds ratio 7.05), a physician global score above 1 (odds ratio 4.02) and low platelets (odds ratio 1.33 for each drop of 50 × 109 per liter). Non-Hispanic white race was linked to lower risk (odds ratio 0.45). Later in pregnancy, flares, higher disease activity and smaller rises in the complement protein C3 also predicted bad outcomes.
The ACR guideline's guiding principles are safe and effective contraception to prevent unplanned pregnancy, and counseling before pregnancy. Six months of quiet lupus — no flare, stable labs, controlled blood pressure, safe medications — is the state rheumatologists describe as the target before trying to conceive. For people newly diagnosed, just off a flare or still adjusting medications, the usual guidance is contraception for now, pregnancy later.
"Quiescent" does not mean "feels fine." It means objective stability: no new clinical activity, stable or rising C3/C4 complement, stable or falling anti-dsDNA, normal blood pressure, no active nephritis on urine studies, and a SLEDAI or physician global assessment that your rheumatologist calls low.
Risk Stratification: Who Counts as High-Risk
Rheumatologists run through a checklist before conception. Any one of the following shifts a pregnancy from "standard" to "high-risk" and changes how closely it is monitored:
- Active lupus within the last 6 months — especially active nephritis.
- History of lupus nephritis, even if currently in remission. Pregnancy can unmask residual inflammation, and prior nephritis raises the risk of preeclampsia 2–3 fold. See Lupus Nephritis.
- Antiphospholipid antibody positivity — lupus anticoagulant, anticardiolipin immunoglobulin G (IgG)/immunoglobulin M (IgM), or anti-beta-2-glycoprotein-I immunoglobulin G/immunoglobulin M. Triple-positive patients are the highest-risk subgroup.
- Anti-Ro/SSA or anti-La/SSB positivity — raises the risk of neonatal lupus and congenital heart block.
- Hypertension at baseline, or proteinuria, or elevated creatinine.
- Prior poor obstetric history — previous late miscarriage, stillbirth, severe preeclampsia, or preterm delivery under 34 weeks.
- Pulmonary hypertension, severe restrictive lung disease, heart failure, or advanced chronic kidney disease (creatinine > 2.8 mg/dL). These are the rare scenarios where pregnancy is considered medically contraindicated because maternal mortality is unacceptably high.
Most patients fall into the "standard-risk lupus pregnancy" category: well-controlled disease, no antiphospholipid antibodies, normal kidneys, normal blood pressure. These pregnancies do extremely well. High-risk pregnancies still usually do well, and they are usually co-managed by a maternal-fetal medicine specialist and a rheumatologist from week one.
Antiphospholipid Syndrome and Anticoagulation
Antiphospholipid antibodies (aPL) — lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein-I — are present in roughly 30–40% of lupus patients. A smaller subset (maybe a third of those) meet clinical criteria for antiphospholipid syndrome (APS), which requires both persistent antibody positivity and a history of thrombosis or pregnancy morbidity (recurrent early loss, fetal loss after 10 weeks, or severe preeclampsia / placental insufficiency requiring preterm delivery).
APS in pregnancy is treatable. The standard regimen:
- Low-dose aspirin 81 mg daily, ideally started before conception and continued throughout pregnancy and into the early postpartum period.
- Prophylactic low-molecular-weight heparin (LMWH) — typically enoxaparin 40 mg subcutaneously once daily — for women with obstetric APS (recurrent loss or prior late fetal loss) but no prior thrombosis.
- Therapeutic-dose LMWH — enoxaparin 1 mg/kg twice daily — for women with a prior thrombotic event.
Older historical comparisons describe live-birth rates in APS pregnancy rising from roughly 20–30% with no treatment to 70–80% with aspirin plus LMWH. That jump has not been tested directly: the 2020 Cochrane review found no trial with an untreated comparison group. Its own results are smaller and less certain. Heparin plus aspirin, compared with aspirin alone, may increase live births (risk ratio 1.27, 95% confidence interval 1.09–1.49; 5 studies, 1,295 women; low certainty), a result driven by one large study. Whether aspirin alone helps compared with placebo is very uncertain (risk ratio 0.94, 95% confidence interval 0.71–1.25; 1 trial of 40 women). Overall the review rated the evidence low to very low certainty.
Warfarin is teratogenic and is not used during pregnancy; direct oral anticoagulants (DOACs like apixaban, rivaroxaban) are not recommended because safety data are inadequate. LMWH, by contrast, does not cross the placenta and has decades of pregnancy safety data.
A newer add-on was tested in the IMPACT trial (2025). Fifty-one high-risk women with APS and lupus anticoagulant received certolizumab pegol, an anti-inflammatory antibody with little or no transfer across the placenta, from week 8 to week 28, on top of heparin and aspirin. The main bad outcome (fetal death after 10 weeks, or severe preeclampsia or placental problems forcing delivery before 34 weeks) occurred in 17.6%, or 20% after excluding early losses and genetic causes, against an expected 40% in similar earlier patients. There was no comparison group in the trial itself. Newborn survival to hospital discharge was 93%, and there were no serious infections.
Aspirin 81 mg is also now recommended by the American College of Obstetricians and Gynecologists (ACOG) and the U.S. Preventive Services Task Force (USPSTF) for people at high risk of preeclampsia, a group that includes lupus and APS, regardless of antiphospholipid status. The USPSTF wording is "after 12 weeks of gestation". Many rheumatologists start it at the positive pregnancy test.
Anti-Ro/SSA, Congenital Heart Block, and Neonatal Lupus
About 30–40% of lupus patients are positive for anti-Ro/SSA antibodies, and a subset also have anti-La/SSB. These antibodies cross the placenta freely starting around week 12. In the fetus, they can bind cardiac tissue and trigger two distinct problems:
Neonatal cutaneous lupus. A transient rash — often on the face and scalp, sometimes triggered by light exposure in the newborn nursery — that appears in the first few weeks of life and resolves spontaneously by 6–8 months as maternal antibodies clear the baby's circulation. It looks alarming but leaves no lasting damage.
Congenital heart block (CHB). The serious one. Maternal anti-Ro antibodies damage the fetal atrioventricular (AV) node, producing complete heart block that is usually permanent. It affects roughly 2% of first pregnancies in anti-Ro-positive women, and the recurrence rate in a subsequent pregnancy after an affected child is 15–20%. Most affected babies need a pacemaker, often within the first year of life. The mortality rate is around 15–20%.
The critical window is weeks 16 to 26 — that's when the fetal conduction system develops and when antibody-mediated damage occurs. What is done in anti-Ro-positive pregnancies:
- A common schedule is weekly or every-two-week fetal echocardiograms from 16 to 26 weeks, then every 2–4 weeks through 34 weeks. The 2017 EULAR (European rheumatology) recommendations separate two groups: weekly scans from 16 weeks for women with a previously affected child (16% recurrence), and, for women with no previous affected child (risk 0.7–2%), they call it unclear whether such intensive monitoring is cost-effective.
- The fetal PR interval is monitored (a measure of AV conduction time). A prolonging PR interval may represent first-degree block and a chance to intervene before complete block sets in.
- If first-degree or second-degree block is caught early, treatment with dexamethasone or intravenous immunoglobulin plus hydroxychloroquine may halt progression in some cases, though evidence is mixed and dexamethasone has its own fetal-growth costs.
- Hydroxychloroquine (HCQ) taken by the mother throughout pregnancy has been studied in the PATCH trial and other studies in anti-Ro-positive women who had a prior affected child. PATCH was open-label and single-arm, with no comparison group: 54 pregnancies, 400 mg daily started before the end of week 10. Second- or third-degree heart block occurred in 4 of 54 (7.4%), against a historical recurrence rate of 18%, which its authors report as a reduction of more than half. Four babies had the temporary skin rash. This is one of the strongest reasons given for continuing HCQ.
Medications Usually Continued
Rheumatologists describe stopping medications out of a vague fear that "drugs are bad for the baby" as one of the most dangerous things that happen before or during a lupus pregnancy. Untreated lupus is far more dangerous to the baby than the drugs below. What the current EULAR and ACR guidelines state:
Hydroxychloroquine (HCQ) — recommended before conception and throughout pregnancy for people with lupus (EULAR 2017). HCQ crosses the placenta. A 2026 pooled analysis of 20 studies found a slight link between first-trimester use and major birth defects (adjusted odds ratio 1.29, 95% confidence interval 1.09–1.53), rated low certainty; its authors said this does not support changing its use in lupus pregnancy, given its benefits. A Swedish national study of lupus births found major birth defects in 3.7% of exposed and 3.4% of unexposed babies, not a significant difference (adjusted risk ratio 1.29, 95% confidence interval 0.65–2.56). HCQ reduces lupus flares, reduces preeclampsia, reduces preterm birth, reduces the risk of congenital heart block in anti-Ro-positive women, and improves live-birth rates. Stopping HCQ in pregnancy is associated with a measurable increase in flares and worse outcomes. Dose is usually 200–400 mg daily. See Hydroxychloroquine and Antimalarials.
Azathioprine — compatible. The fetal liver lacks the enzyme (inosinate pyrophosphorylase) needed to convert azathioprine to its active metabolite, so fetal drug exposure is limited. Azathioprine up to 2 mg/kg/day is standard for lupus nephritis maintenance in pregnancy and is compatible with breastfeeding.
Tacrolimus — compatible. Often used in active or prior lupus nephritis during pregnancy. Trough levels are monitored monthly because pregnancy changes drug clearance.
Prednisone — the lowest effective dose. Prednisone is extensively metabolized by placental 11-beta-hydroxysteroid dehydrogenase, so only about 10% reaches the fetus. Low doses (under 10–15 mg/day) are generally considered acceptable. Higher doses carry real risks: maternal hypertension, gestational diabetes, preeclampsia, preterm rupture of membranes, and cleft palate if used in high doses in the first trimester. Prednisone is described as a treatment for flares, not a long-term ceiling. Dexamethasone and betamethasone do cross the placenta and are reserved for fetal indications (lung maturity before preterm delivery, or congenital heart block treatment).
Cyclosporine — compatible. Less commonly used than tacrolimus but acceptable.
Sulfasalazine — compatible. Rarely used in lupus but worth knowing.
Low-dose aspirin 81 mg — started during pregnancy. See the APS and preeclampsia-prevention discussion above.
LMWH — used as indicated. Does not cross the placenta.
Medications Stopped Before Conception
Several lupus drugs are clearly teratogenic or associated with serious fetal harm. The 2017 EULAR recommendations state that mycophenolic acid, cyclophosphamide, leflunomide and methotrexate should be avoided in pregnancy, so they are stopped before trying to conceive, with washout periods built into the timing.
Methotrexate — stopped before conception. Causes miscarriage and a specific pattern of birth defects (craniofacial, limb, central nervous system). Washout: 3 months before conception (the drug sits in tissues well beyond its plasma half-life). People on methotrexate who are planning pregnancy are usually switched to azathioprine or another compatible agent three months before trying, with folic acid supplements throughout the transition.
Mycophenolate mofetil (MMF) — stopped before conception. A potent teratogen. Causes a characteristic pattern of congenital malformations (cleft lip/palate, ear malformations, cardiac defects, microtia) and early miscarriage. This is one of the most important drug-switch conversations a lupus nephritis patient will have. Washout: 6 weeks minimum, but most specialists want the switch done and the patient stable on azathioprine or tacrolimus for 3–6 months before conception. The usual guidance is contraception for both partners while either is on MMF.
Cyclophosphamide — stopped before conception. Teratogenic, causes infertility, and is reserved for severe disease. Not used in pregnancy except in true life-threatening maternal indications after the first trimester.
Leflunomide — stopped with an active washout. Leflunomide's active metabolite has a half-life of weeks and can persist for up to two years. The washout protocol uses cholestyramine 8 g three times daily for 11 days, followed by two separate blood levels (at least 14 days apart) showing serum concentrations below 0.02 mg/L, before conception is safe.
Warfarin — switched to LMWH. Teratogenic in the first trimester (warfarin embryopathy) and raises fetal bleeding risk later. The move to therapeutic-dose LMWH is made before conception or at the positive pregnancy test.
Angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) — stopped. Cause fetal renal dysgenesis, oligohydramnios, and lung hypoplasia, particularly in the second and third trimesters. Labetalol, nifedipine, or methyldopa are the usual substitutes for blood pressure control.
Nonsteroidal anti-inflammatory drugs (NSAIDs) — limited use. The U.S. Food and Drug Administration (FDA) warns against use after 20 weeks (oligohydramnios and renal dysfunction); use after 30 weeks carries premature closure of the ductus arteriosus. Short-term use in the first and early second trimester is generally acceptable if clearly needed.
Biologics — Belimumab, Rituximab, and Anifrolumab
The biologic lupus drugs are newer and pregnancy data are thinner. The general framework: immunoglobulin G monoclonal antibodies cross the placenta actively via the neonatal Fc receptor starting in the second trimester and rising steeply through the third. That means late-pregnancy dosing delivers the highest fetal exposure — which matters for vaccination decisions in the baby's first six months (live vaccines are delayed in infants exposed to biologics late in pregnancy).
Belimumab. An anti-BLyS monoclonal antibody. Pregnancy safety data are limited but expanding. The largest summary (2023) covers 319 pregnancies with known outcomes. Birth defects were found in 4 of 72 (5.6%) in clinical trials, 10 of 46 (21.7%) in the pregnancy registry's prospective group and 1 of 92 (1.1%) in postmarketing reports, with no consistent pattern. Every exposed woman in the trials and the registry also took other medicines and had confounding factors or missing data, and the authors say low numbers, confounding and incomplete information preclude informed recommendations on risk. Current practice: belimumab is usually not started in a woman trying to conceive, but if a patient is stable and well-controlled on it and pregnancy occurs, shared decision-making often continues it, sometimes dropping the last dose in the third trimester. See Biologics in Lupus.
Rituximab. An anti-CD20 monoclonal. First-trimester exposure is generally considered low-risk (placental transfer is minimal before week 16). The second and third trimesters are the concern: rituximab crosses the placenta heavily in later pregnancy and causes transient B-cell depletion in the newborn, which can last several months and interferes with vaccine responses and infection defense. When rituximab is medically necessary, infusions are usually timed so that the last dose is at least several months before conception when possible.
Anifrolumab. A type-I interferon receptor antibody approved for moderate-to-severe systemic lupus erythematosus (SLE) in 2021. Pregnancy data are essentially absent. Current guidance is against use during pregnancy. It lists effective contraception for women of reproductive age on anifrolumab, and stopping the drug before conception with a reasonable washout.
Preeclampsia vs. Lupus Flare
This is the single hardest clinical problem in lupus pregnancy, and understanding it will help you advocate for yourself when you're in triage at 3 a.m. in the third trimester. Both preeclampsia and a lupus flare can present with:
- Rising blood pressure
- Proteinuria
- Edema
- Thrombocytopenia
- Headache
- A feeling of "something is wrong"
They require opposite treatments. Preeclampsia is treated by delivering the baby — the placenta is the problem. A lupus flare is treated by intensifying immunosuppression, and delivering the baby won't fix it. Getting this wrong in either direction is harmful.
Features that suggest preeclampsia over lupus flare:
- Onset after 20 weeks (preeclampsia is very rare before 20 weeks except in the setting of molar pregnancy or severe APS)
- New or rising uric acid
- Rising liver transaminases (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)) — the "H" and "EL" of HELLP syndrome
- Normal or rising complement (C3, C4)
- Normal or stable anti-dsDNA titers
- No active findings elsewhere (no new rash, no synovitis, no serositis, no oral ulcers)
- Rapid resolution within 24–48 hours of delivery
Features that suggest a lupus flare:
- Falling complement (C3 and C4 drop)
- Rising anti-dsDNA
- Active urinary sediment (red-cell casts, dysmorphic RBCs)
- Low C1q level or positive anti-C1q antibodies
- Extra-renal lupus activity: new rash, arthritis, oral ulcers, pleuritis, pericarditis, hair loss
- Onset before 20 weeks
- No improvement after delivery
In practice, patients often have both — preeclampsia and a lupus flare can and do coexist, especially in women with prior lupus nephritis. That's one reason the co-management model (rheumatologist plus maternal-fetal medicine plus nephrologist if needed) is standard of care.
Prenatal Monitoring Schedule
A typical lupus pregnancy monitoring plan, modified for risk level:
- Preconception: baseline complete blood count (CBC), creatinine, urinalysis, spot urine protein/creatinine ratio, C3, C4, anti-dsDNA, anti-Ro/SSA, anti-La/SSB, full antiphospholipid panel (lupus anticoagulant, anticardiolipin immunoglobulin G/immunoglobulin M, anti-beta-2-GPI immunoglobulin G/immunoglobulin M), thyroid-stimulating hormone (TSH), vitamin D. Blood pressure control, HCQ dose review, and stopping teratogens with washout.
- First trimester: early dating ultrasound; confirm medication list; aspirin 81 mg starts around 12 weeks (USPSTF wording: after 12 weeks of gestation; many rheumatologists start earlier); repeat labs above at 8–12 weeks.
- Second trimester: detailed anatomy scan at 18–20 weeks; lupus labs every 4–6 weeks (or monthly if high-risk); uterine artery Dopplers around 20–24 weeks in high-risk patients; fetal echocardiography weekly from week 16 in anti-Ro-positive women with a previously affected child; for those without one, a common schedule is weekly or biweekly from week 16 to week 26, then every 2–4 weeks until 34 weeks, though EULAR calls it unclear whether that intensity is cost-effective.
- Third trimester: growth ultrasounds every 3–4 weeks (lupus raises the risk of intrauterine growth restriction); antenatal fetal testing (non-stress tests, biophysical profiles) starting around 32 weeks in high-risk patients; continue lupus labs monthly.
- Delivery planning: most lupus patients can aim for vaginal delivery at term. Cesarean for obstetric indications. As a 2026 review summarizes it, the 2020 ACR guideline conditionally recommends against routine stress-dose steroids during vaginal delivery, and conditionally recommends them at surgical delivery in people taking more than 5 mg of prednisone a day for more than 4 weeks.
Delivery and Postpartum
The postpartum period is a high-risk window for lupus flare. Rates of flare in the first 3–6 months after delivery are higher than the baseline flare rate, driven partly by immune-system rebound and partly by sleep deprivation, stress, and breastfeeding hormones.
Expect:
- A rheumatology visit within 4–6 weeks after delivery (sooner if symptoms).
- Continued aspirin 81 mg for 1–6 weeks postpartum.
- Continued LMWH for 6 weeks postpartum in APS patients (the highest thrombosis risk of the whole pregnancy cycle is the first six postpartum weeks).
- Contraception counseling. Estrogen-containing contraceptives (combined pills, patch, ring) are contraindicated in APS-positive women and relatively contraindicated in active lupus because of thrombosis risk. Progestin-only pills, the levonorgestrel IUD, the copper IUD, and the subdermal implant are all safe. This is usually discussed before discharge.
Breastfeeding
Most lupus medications are compatible with breastfeeding at the doses used in clinical practice. Specifically:
- Hydroxychloroquine — compatible. Minimal infant exposure via breast milk.
- Azathioprine — compatible. Active metabolite levels in breast milk are negligible.
- Tacrolimus, cyclosporine — compatible.
- Prednisone — compatible. At doses over 20 mg/day, some clinicians recommend waiting 4 hours between a dose and a feed, though this is more tradition than strong evidence.
- Nonsteroidal anti-inflammatory drugs (ibuprofen, etc.) — compatible short-term; ibuprofen is the usual first choice.
- Warfarin — compatible (does not enter breast milk in clinically significant amounts).
- LMWH — compatible (too large to pass into milk, and not orally absorbed by the infant anyway).
- Belimumab, rituximab, anifrolumab — limited data; immunoglobulin G antibodies in breast milk are mostly digested in the infant gut, so transfer is thought to be low, but shared decision-making is required.
- Methotrexate, mycophenolate, cyclophosphamide, leflunomide — contraindicated during breastfeeding, the same way they are in pregnancy.
For infants whose mothers received biologics late in pregnancy, live vaccines (rotavirus, later MMR) are deferred until the baby's drug level has cleared — typically at least 6 months of age, sometimes longer depending on the drug. Inactivated vaccines (DTaP, Hib, pneumococcal, hepatitis B, inactivated polio) are given on the normal schedule.
Key Research Papers
- Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015 (PROMISSE). — doi:10.7326/M14-2235
- Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with SLE and/or antiphospholipid syndrome. Ann Rheum Dis. 2017. — doi:10.1136/annrheumdis-2016-209770
- Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020. — doi:10.1002/art.41191
- Izmirly P, Kim M, Friedman DM, et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers. J Am Coll Cardiol. 2020 (PATCH). — doi:10.1016/j.jacc.2020.05.045
- Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;(2):CD002859. — PubMed PMID: 15846641
- Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15–29. — doi:10.1136/ard-2023-224762
- Hamulýak EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020;5(5):CD012852. — PubMed PMID: 32358837
- Branch DW, Kim MY, Guerra MM, et al. Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial. Ann Rheum Dis. 2025;84(6):1011–1022. — PubMed PMID: 40483169
- Cournand E, Teboul A, Costedoat-Chalumeau N, et al. First trimester exposure to hydroxychloroquine during pregnancy and major congenital malformations: a systematic review and meta-analysis. RMD Open. 2026;12(4). — PubMed PMID: 42933791
- Nguyen NV, Svenungsson E, Dominicus A, et al. Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study. Rheumatology (Oxford). 2025;64(1):117–125. — PubMed PMID: 38479815
- Petri M, Landy H, Clowse MEB, et al. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 2023;82(2):217–225. — PubMed PMID: 36198440
- Amiri N, Gamble M, Laskin C, Pavlova V, Troster S. A clinical care pathway for managing pregnancy in patients with inflammatory arthritis. Clin Rheumatol. 2026;45(1):13–28. — PubMed PMID: 41324720
PubMed Topic Searches
For further reading, the following PubMed topic searches return current peer-reviewed work on lupus pregnancy:
- PubMed: PROMISSE and lupus pregnancy outcomes
- PubMed: Antiphospholipid syndrome, aspirin, and LMWH in pregnancy
- PubMed: Anti-Ro/SSA and congenital heart block
- PubMed: Hydroxychloroquine in lupus pregnancy
- PubMed: Mycophenolate teratogenicity
- PubMed: Preeclampsia vs. lupus flare differentiation
- PubMed: Belimumab pregnancy registry data
- PubMed: Lupus nephritis and pregnancy outcomes
- PubMed: Neonatal cutaneous lupus
- PubMed: Lupus medications and breastfeeding
Connections
- Rheumatology
- Lupus Overview
- Hydroxychloroquine and Antimalarials
- Biologics: Belimumab, Anifrolumab and Rituximab
- Lupus Nephritis and Kidney Involvement
- Preeclampsia
- Neuropsychiatric Lupus
- ACR-EULAR 2019 Classification Criteria
- Cutaneous Lupus and Photoprotection
- Lupus-Sjogren's Overlap
- Antinuclear Antibody, dsDNA and Lupus Autoantibodies
- Sjogren's Syndrome
- Pregnancy and Hashimoto's
- Pregnancy and Inflammatory Bowel Disease
- Gestational Diabetes
- Kidney Disease